Company / R&D Expense
Janux Therapeutics, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$125.9M
FY2025
5-year range
$26.2M / $125.9M
FY2021-FY2025
Trend
+84.1%
vs FY2024
Sector context
#118 of 209
Health Care
What the data says
At $126M, Janux Therapeutics, Inc.'s r&d expense ranks #118 of 209 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $3M in FY2020 to $126M in FY2025.
Based on SEC 10-K filings.
$126M in FY2025 with a 5-year CAGR of +110.6%.
Improved from $55M to $126M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +33.1%
- 5-Year CAGR
- +110.6%
- 10-Year CAGR
- -
Sector benchmark
#118 of 209 in Health CareTop 56% of 209This company $125.9M Sector average $647.6M
▼
-80.6% below sector average
Key checks
Key Insights
- Janux Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +110.6%, indicating consistent growth.
- In FY2025, r&d expense increased 84.1% year-over-year.
- Ranks #118 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $125.9M | +84.1% |
| FY2024 | $68.4M | +24.5% |
| FY2023 | $54.9M | +2.8% |
| FY2022 | $53.4M | +103.7% |
| FY2021 | $26.2M | +762.8% |
| FY2020 | $3.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026